Running Head: SPECT/CT of bronchial deposition
ENGLISH SUMMARY
Aims-Vaccination by aerosol inhalation can be used to efficiently deliver antigen against HPV to mucosal tissue, which is particularly useful in developing countries (simplicity of administration, costs, no need for cold chain). For optimal immunological response, vaccine particles should preferentially be delivered to proximal bronchial airways. We aimed at quantifying the deposition of inhaled particles in central airways and peripheral lung, and to assess administration biosafety.
Methods-Twenty healthy volunteers (13W/7M, aged 24±4y) performed a 10-min free-breathing inhalation of 99m
Tc-stannous chloride colloid aerosol (450 MBq) in a buffer solution without vaccinal particles using an ultrasonic nebulizer (mass median aerodynamic diameter 4.2 µm) and a double mask inside a biosafety cabinet dedicated to assess environmental particle release. SPECT/CT and whole-body planar scintigraphy were acquired to determine whole-body and regional C/P distribution ratio (central-to-peripheral pulmonary deposition counts). Using a phantom, SPECT sensitivity was calibrated to obtain absolute pulmonary activity deposited by inhalation.
Results-All participants successfully performed the inhalation that was well tolerated (no change in pulmonary peak expiratory flow rate, P = 0.9). 
INTRODUCTION
Vaccines constitute one of the most cost-effective preventive measures against illness and death from infectious disease [23] . Each year, five million people die worldwide from mucosally transmitted diseases that might be prevented by vaccines [8] . Cervical cancer is the second most common cancer in women in the world, the most common in Africa and the leading cause of cancer deaths in developing countries [4] . Vaccines against the leading HPV oncogenic types 16 and 18 are available with efficacy exceeding 95% in HPV-uninfected women [37] . However, efficient vaccination programs are difficult to implement in developing countries mainly because of currently prohibitive costs.
Despite the unprecedented medical success of vaccination, traditional application routes (intramuscular or subcutaneous) are not without limitations. In the context of mass vaccination campaigns in developing countries, needle-free vaccination can increase compliance (reduced local pain and side effects) and decrease overall costs (no need for needle disposal, etc.) Specific vaccine formulations abolish the need for a "cold chain" (specific equipment, and procedures to maintain vaccine at low temperatures until administration) [19, 24, 28] and aerosol immunization is such an alternative. This is offering many advantages: ease of application by paramedical personnel, lesser invasiveness favouring acceptance, reduced risk of cross-contamination by blood-born infectious agents, diminished Page 8 medical waste, and lower costs thanks to the use of multidose vials, among others [2, 21] . Moreover, aerosol vaccination may induce better immunogenicity than conventional subcutaneous injections [8] because mucosal immune response might induce broader protection due to the production of IgA in addition to systemic IgG antibodies [30, 39] .
Nuclear medicine is a unique resource for the translational research about therapies delivered as aerosols. Indeed, for both research and development SPECT or PET of aerosol lung deposition is the most relevant strategy to pre-clinically assess the actual dose delivered to the target area [7, 9, 15] . At the time of translation to clinical trials, lung deposition imaging allows to optimize aerosol delivery to the target for immunization (central lung) while minimizing potential side effects due to deposition in less effective area (peripheral lung).
In a preclinical validation study in non-human primates, Corbett et al. [8] showed that aerosol-delivered poxvirus-based vaccination was safe, feasible, and immunogenic. The next step towards clinical implementation consists in validating this aerosol vaccination in humans. However, before dose escalation and safety analysis of side effects, more information needs to be collected about vaccinal particle charge and lung distribution during the face-mask aerosol nebulization [39] . Thus, the aims of our study were:
(1) to assess the fraction of the nebulized particles delivered to the lungs to decide about the future viral charge; (2) to demonstrate a privileged deposition of aerosolized particles into the central part of the lungs to elicit optimal immunological response, while limiting the alveolar exposure (not essential to proper immunization) and potential inflammation; and (3) to verify administration safety by quantifying environmental particle release.
METHODS

Study population
Healthy volunteers were prospectively recruited by advertisement at the Lausanne University Hospital, Switzerland. Before inclusion, they underwent history taking (personal medical history including pulmonary disease, infectious disease, smoking, asthma and chronic obstructive pulmonary disease) and a physical examination. Peak expiratory flow rate (PEFR) was measured immediately before and after inhalation as a simple surrogate for asthma detection and to detect any subclinical change due to the aerosol-induced broncho-constrictive reaction. Women of childbearing age underwent a pregnancy test; a negative result was required before inclusion. The Local Ethic Committee, the Swiss Federal Office of Public Health and Swissmedic approved the study protocol and participants signed a written informed consent form. Participants received a total effective dose of 1.9 mSv (1.0 mSv from the radiotracer and 0.9 mSv for the lowdose/slow-rotating CT) [36] . The radiation effective dose was obtained by Page 10 assuming that a maximum of 17% of the nebulized activity would be distributed in the patient based on a preclinical study [26] and an effective dose ED of 0.014 mSv/MBq computed from known organ distribution of nanocolloid aerosol (Venticoll™, GE Healthcare Srl, Milano, Italy) and ICRP 60 tissue weighting factors.
Radiolabeling of particles and nebulization procedure
The deposition procedure used non-viral, inert stannous chloride particles titrated with 5N HCl for pH 8.0). As previously described [26] , aerosol generated from such a formulation exhibits the same granulometry and lung deposition pattern as the vaccine due to the low protein content. Labeling was performed according to the manufacturer instructions [34] . Preliminary measurements were conducted to verify labeling and particle size stability in the buffer solution (pH 8) during nebulization (data not shown).
An ultrasonic nebulizer (Atomisor Megahertz AMGH, La Diffusion
Technique, St-Etienne, France) was used to create aerosol from radiolabeled solution. Using a nebulization power set at 10/10, a 4.2 µm mass median Page 11 aerodynamic diameter (MMAD) aerosol was generated to favour central pulmonary distribution with care to prevent any temperature increase during sonication. To further privilege central pulmonary distribution of the aerosol, we chose active inhalation with disconnected internal ventilator and set tubing lengths 1 and 2 to get 75-and 300-ml buffer volumes, respectively ( Figure 1A) . For the inhalation process, the subject was placed in front of a biosafety cabinet containing a class-E12 HEPA filter, and equipped with a Double Mask system (Medicvent, Umeå, Sweden). The soft inner mask was connected to the nebulizer chamber and the hard outer mask evacuation outlet was connected to the biosafety cabinet aspiration through a separate HEPA filter to trap any aerosol particle escaping from the inner mask. The participants were instructed to freely inhale the nebulized aerosol in a controlled and reproducible tidal breathing manner for 10 minutes [27] .
Residual activity in the nebulizer reservoir and tubing system was measured before and after the aerosol delivery. The activity released in the environment from the nebulization procedure was aspirated through the biosafety cabinet HEPA filter, whose activity was measured distant from the participant outside the administration room.
Imaging acquisition and processing
Twenty minutes after inhalation every participant underwent a SPECT/CT acquisition (Hawkeye IV, GE Healthcare, Milwaukee, MI) using an energy Then, the absolute central pulmonary deposition CPD can be derived as 
RESULTS
Population
Twenty-one healthy volunteers were enrolled and complete data were available in twenty participants (13 women, 7 men) aged 24±4 years. None had history of asthma or any other chronic or recent pulmonary condition; 5
were smokers (25%). Pulmonary auscultation was unremarkable in all participants and peak expiratory flow rate was within normal range for age and sex ( Table 1) .
Inhalation and procedure safety
The 10.0-min nebulization could be performed safely in all participants with an activity of 430±20 MBq of 
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The nebulization was also safe for the environment; no activity was released from the nebulization system or from the double mask in the biosafety cabinet HEPA filter. At the end of the inhalation, the nebulization system contained >90% of the activity, with the largest activity in the nebulization chamber (Fig. 1A and 1B) .
Inhaled particle distribution
Whole-body scans revealed that inhaled particles were mainly localized in respiratory and digestive tracts, i.e. the mouth/oropharynx (N = 20), esophagus (N = 9), stomach (N = 17) and bowel (N = 13) due to saliva swallowing ( Figure 1C) . Of note, minimal activity could be seen in the bladder (N = 2, different than the one of Figure 1 ) and no activity was seen in the liver, spleen, kidney, thyroid or bone marrow.
On planar scintigraphy, lung activity represented 40±9% of the total whole-body activity. There was no difference according to gender (women 38±8% vs. men 43±11%, P=0.4) or to smoking status (non-smokers 39±10% vs. smokers 43±6%, P = 0.2). On SPECT images, 54±4% particles were localized in the right lung and 46±4% in the left lung (P < 0.0001).
This relative distribution was neither influenced by gender (P = 0.7) nor by smoking status (P = 0.6). There was also no significant difference between upper, middle and lower third of lung fields (P > 0.6).
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Total pulmonary deposition, TPD was 1.3±0.6% (range 0.4-2.6%) of the total activity initially present in the nebulizer (Fig. 2) . Residual inhaled particles were also seen on SPECT/CT in the trachea (N = 13) and on the skin (N = 9) due to salivary contamination from the mouth after inhalation. There was no significant difference between men and women (1.4±0.7% vs. 1.2±0.6%, P = 0.9) or between smokers and non-smokers (1.4±0.7% vs. 1.2±0.6%, P = 0.7).
Regional lung distribution of inhaled particles
SPECT/CT showed a central to peripheral deposition ratio C/P of 0.4±0.2 (range 0.15-1.14) and a central pulmonary deposition CPD of 0.3±0.3%
(range 0.1-1.4) (Fig. 2 ). An example is illustrated in Fig. 3 , with VOI drawn for computing the central and peripheral activity. The C/P ratio was not affected by the smoking status (non-smokers 0.36±0.11 vs. smokers 0.51±0.36, P = 0.6), but tended to be higher for women than men (0.46±0.22 vs. 0.30±0.11, P = 0.06). Of note, C/P ratio was significantly correlated with PEFR (ρ = -0.58, P = 0.01).
The semi-quantitative C/P index showed a favourable central distribution with 11/20 (55%) of the participants showing a marked or very strong uptake and 15/20 (75%) showing a higher uptake in central regions than in parenchyma (grade 2 or above) (Fig. 4) .
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DISCUSSION
Thanks to the use of scintigraphic imaging to optimize the deposition within the central lung, preclinical studies of aerosol administration poxvirus-based vaccines in non-human primates have led to a safe and long-lasting immune response [8, 26] . Here, we performed a proof-ofconcept study in volunteers to assess the feasibility of aerosol nebulization, including the basic safety profile of non-vaccinal buffer solution at the individual and environmental level, and to quantify regional distribution. Our results demonstrate that quantification of the regional distribution of radiolabeled aerosols in a human vaccine model without immunogenic particles is feasible. Moreover, the administration is safe for the participants and the environment. These results are encouraging for future vaccine application trials in humans, where the full safety profile and immune response will be assessed.
Within the lung, several factors may influence the site of particle deposition, the size being one of the most important [18] . Particle sizes of 4-5µm, such as the one produced in our study are thought to be optimal for a central deposition of an aerosol in the lungs [5] . The central lung is considered as the target area to elicit optimal immunological response [1, 3, 8, 29, 33] . The human upper airway mucosa contains a dense network of antigen-presenting cells throughout the nasal cavity, trachea, and lungs ready to initiate immune response when in contact with a microbial burden Page 18 [20] . During inspiration, larger particles will be deposited merely in the tubing system and smaller ones in the peripheral part of the lung [2, 6, 10] .
Planar gamma camera scintigraphy is well established for measuring deposition of radioaerosols [11, 38] . SPECT /CT provides 3-dimensional, detailed information and offers a superior assessment of aerosol deposition [13, 14, 16] . In addition, we performed CT-based attenuation corrections of the SPECT images and used a calibration factor derived from a phantom to more accurately assess the activity deposited in target regions [27] . Our results support the feasibility of aerosol delivery of vaccines with preferred central lung distribution, in agreement with previous results in a series of 8 non-human primates [8] .
The efficacy of inhaled drugs, whether given for treatment of lung disease [17, 25, 32, 35] or to achieve an effect in some other part of the body, depends on drug deposition in the lungs. Our results with mean lung deposition TPD of 1.3±0.6% of the total nebulized activity were within range of values observed in the preclinical non-human primate study (3.6±1.1% and 1.8±0.5% for two different strains of poxvirus-based vaccine) [8] . Although this figure may seem low, it was sufficient to elicit durable vaccine immune response [8] . Similarly, our central-to-peripheral deposition ratio reached 0.4±0.2, close to the non-human primate preclinical values (C/P = 0.75 in average) [8] and is in agreement with our A few limitations to our study need to be mentioned. This study was performed in healthy participants. However, in patients with airway disease, aerosol deposition can be different, namely with a more pronounced central deposition and a potentially faster washout of centrally deposited aerosols by mucociliary clearance or cough reflex [12] . However, this
should not be a major problem in the proposed HPV vaccine model, as potential subjects would be young, non-HPV-exposed and devoid of lung disease. It is also worth mentioning that non-human primates were pretreated with atropine not only to reduce salivation, but also to get transient inhibition of the bronchial mucociliary clearance and favour antigen presentation; thus, the effect of mucociliary clearance or its transient inhibition need obviously to be specifically studied. This was not done in this study on volunteers and could have influenced the results. Moreover, Page 20
non-human primate results were also developed using planar scintigraphy and there are known differences between regional pulmonary depositions measured on 2-D planar scans and 3-D SPECT [14] . Finally, the assessment of nebulized particles could also be performed by PET with several advantages over SPECT (absolute quantitation without the need of a calibration standard, shorter isotope half-life) [31] but the labelling of aerosols with positron emitters remains challenging. 13 NH2 has been employed to image saline-based aerosols but requires an on-site cyclotron [40] . Tc to label kit-based radiopharmaceuticals [22] .
In conclusion, we demonstrated a feasible and safe method for 
